Publication for CD34 and CDH5

Species Symbol Function* Entrez Gene ID* Other ID Gene
coexpression		 CoexViewer
hsa CD34 CD34 molecule 947 [link]
hsa CDH5 cadherin 5 1003

Pubmed ID Priority Text
22214418 0.98 CD34+/KDR+ decrease and subsequent differentiation-related CD34+/CD144+ increase which has been related to statins.
0.97 CD34+/CD144+ cells in CABG patients compared to valvular patients (0.21 +- 0.03% vs. 0.47 +- 0.08%), and this difference remained statistically significant after the P was adjusted for multiple comparisons (P = 0.01428).
0.97 CD34+/CD144+ (r2 = 0.021, P = 0.41 for mean gradient and r2 = 0.015 and P = 0.48 for valve area, respectively).
0.97 CD34+/CD144+ cell numbers after this analysis was performed (P = 0.01428 after Bonferroni adjustment).
0.97 CD34+/CD144+ cells even after the P value was adjusted to the number of comparisons (Table 4).
0.96 CD34+/CD144+ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients
0.96 CD34+/CD144+ numbers have been described in atherosclerotic patients, as well as the role of statins to differentiate CD34+/KDR+ to CD34+/CD144+ .
0.96 CD34+/CD144+ cells.
0.96 CD34+/CD144+ numbers
0.96 CD34+/CD144+ cells in the peripheral blood of cardiac surgery patients (both CABG and valvular) is higher than reported elsewhere for CD34+/KDR+ , and than the one which was obtained by us in a cohort of healthy volunteers.
0.95 CD34+/CD144+ cells compared to valvular surgery patients, in a significant manner.
0.95 CD34+/CD144+ per mul remained lower in the valvualr group compared to the patients who underwent CABG, whereas CD34+/KDR+ remained unchanged.
0.95 CD34+/CD144+ numbers in CABG patients (Table 3).
0.95 CD34+/CD144+ is considered as a more differentiated EPC phenotype, it could be postulated that this advanced differentiation may be disrupted in CABG patients due to a longer history of atherosclerotic vascular damage.
0.93 CD34+/CD144+ cells between these two groups.
0.92 CD34+/CD144+ cells in the pre-surgical blood of patients who underwent CABG surgery compared to aortic stenosis valvular replacement patients (Figure 3, panel B).
0.92 CD34+/CD144+ cells compared to healthy controls.
0.91 CD34+/KDR+ and CD34+/CD144+ cells in CABG patients, compared to aortic stenosis valvular replacement patients.
0.91 CD34+/CD144+ may be mediated by different clinical and analytical parameters between CABG and aortic stenosis valvular patients, intragroup analysis using these parameters were made.
0.87 CD34+/CD144+ cells compared to healthy volunteers without cardiovascular risk factors (Figure 3).
0.86 CD34+/CD144+ and CD34+/KDR+ cells in the peripheral blood of patients undergoing coronary artery bypass grafting (CABG) with angiographic demonstration of CAD, compared to valvular surgery patients with angiographic demonstration of absence of CAD.
0.85 CD34+/CD144+ counts.
0.82 CD34+/CD144+.
24810299 0.98 CD34+CD14-, CD34-CD14-, CD14+) among hESC-derived VEC+CD31+ cells were sorted onto 96 well plates (1 cell/well) and cultured under endothelial cell conditions for 14 days.
0.97 VEC+CD31+CD34+CD14- EPs, through KDR+ mesodermal precursors.
0.96 VEC+CD31+ ECs, specifically CD34+CD14- EPs, whereas VEGF-A and rhDll4 decreased ratios of both VEC+CD31+ ECs and CD34+CD14- EPs among ECs (Figure 3I).
0.96 VEC+CD31+CD34+CD14-KDRhigh EPs was exclusively restricted to mature, fully differentiated ECs, and formed functional capillaries in vivo.
0.96 VEC+CD31+CD34+CD14-).
0.95 VEC+CD31+CD34+CD14- cells contain a discriminative EP population, and thereafter, we named this population as human PSC-derived EP.
0.95 VEC+CD31+CD34+CD14-KDRhigh EPs among VEC+CD31+ ECs (Figure 3I).
0.95 CD34+CD14- subpopulation among VEC+CD31+ ECs represents an endothelial progenitor population, and Notch signaling controls their proliferation or further maturation.
0.95 VEC+CD31+CD34+CD14- cells among VEC+CD31+ cells on day 14. 1 x 104 VEC+CD31+CD34+CD14- cells (EPs) were sorted on day 6 and cultured with VEGF-A with or without rhDll4 or DAPT in phase 3.
0.93 VEC+CD31+CD34+CD14-) is illustrated in Figure 6A and consists of a stepwise combination of treatment with: (1) BMP4 and GSK-3betaI in phase 1 (day 1-4); and (2) DAPT and VEGF-A with PLGF and HGF in phase 2 (day 4-6), using method B described above.
0.93 VEC+CD31+CD34+CD14-) sorted on day 6, ECs (VEC+CD31+) sorted on day 14 or VEC-EGFP+ HUVECs were positively correlated with quantitative total tube area in in vivo Matrigel plugs.
0.92 VEC+CD31+ ECs on day 6 into three subpopulations by the presence or absence of CD34 and CD14 for further analyses examining EP characteristics of these subpopulations (Figure 2B).
0.92 VEC, CD34, and CD14 was evaluated with FACS on day 6 in endothelial differentiation of the Tet-inducible shRNA hESCs.
0.91 VEC+CD31+CD34+CD14- EPs harvested on day 6 of hPSC differentiation and VEC+CD31+ ECs harvested on day 14 of hPSC differentiation or HUVECs revealed that grafted EPs exhibited an increased (three to fivefold) capacity to form vascular networks in vivo after grafting, compared to VEC+CD31+ ECs or HUVECs (Figure 6H).
0.91 VEC+ ECs and CD34+CD14- EPs among ECs compared to control (non-targeting shRNA-transduced hESCs).
0.86 VEC-EGFP. (E) Expression of CD34 and KDR on day 14 in the cultured cells derived from the EPs (VEC+CD31+CD34+CD14-) sorted on day 6.
0.85 CD34+CD14- EC-derived cells after several passages could hold the endothelial lineage phenotype, represented by expression of PECAM1, ENG, CDH5, and NOS3, although expression of EP-related genes had already been decreased (Figure 2I and 2J).
0.74 VE-cadherin (VEC)+CD31+CD34+CD14- cells.
0.58 VEC+ cells sorted on day 6 co-expressed CD31 and KDR, and the majority (60% - 75%) were also expressing CD34 (Figure 2A).
0.56 VEC+CD31+CD34+CD14-KDRhigh endothelial progenitors (EPs) that exhibited higher angiogenic and clonogenic proliferation potential among endothelial lineage cells.
29478891 0.98 CD34 (349x), and CDH5 (1,390x) genes were upregulated in CD31Int versus CD31Neg (Figure 4C, p < 0.01), with the expression of key endothelial genes in CD31Lo cells being lower than in the CD31Int population, PECAM-1 (0.1x), CD34 (0.6x), and CDH5 (0.7x) (Figure 4C).
0.98 CD34 and CD144 antibodies.
0.98 CD34, and CD144) compared with the CD31Int population (Figure 7E).
0.97 CD34, alpha-SMA, and CD45, but homogeneously labeled with vimentin, UEA-1, CD31, and CD144 as would be expected from ECFCs (Figure 2B).
0.97 CD34+ cells obtained from placental cell suspensions, CD31Neg cells were CD144 negative based on FMO analysis (Figure 5B).
0.97 CD34+ populations were sorted based on CD31 and CD144 expression levels after gating on CD45-CD34+ population (Figures 5B and 5C) and cultured in EGM2.
0.97 CD144 allowed a further 4.8-fold enrichment in EPCs as identified by CD31Int expression and a 9.4-fold enrichment in meso-endothelial progenitors, since 3,186 colonies per million seeded cells could be obtained in CD45-CD34+CD31LoCD144+ (compared with 336 colonies [Figure 1I] if using CD45-CD34+CD31Lo alone) (Figure 5E).
0.95 CD34+ populations were examined for CD144 expression in vivo.
0.93 CD34, and CD144) was not affected in the presence of SB431542 compared with the CD31Int population.
0.92 CD34+OPN+ or CD144+OPN+ cells were in the intima of blood vessels.
0.91 CD34+ (reviewed in), highlighting the need for additional markers such as CD31, CD144, or UEA-I. Precise cell surface markers for mesenchymal progenitors (CD45-CD34+CD31-CD144-UEA-I-), EPCs (CD45-CD34+CD31IntCD144+UEA-I-), and meso-endothelial bipotent progenitors (CD45-CD34+CD31LoCD144+UEA-I-) were established, while use of CD90, CD105, CD106, and CD146 documented the expected phenotype of endothelial versus mesenchymal potential.
0.64 CD34, alpha-SMA, and CD45, but labeled with vimentin, UEA-1, CD31, and CD144.
0.58 CD144) and pure endothelial (positive for CD31, CD34, CD144, and CD146 and negative for CD90, CD45, CD106, and CD117) progenitors in CD31Neg and CD31Int populations, respectively (Figure S4).
0.55 CD34+ populations in vivo to analyze CD144 expression.
27118976 0.98 CD144+ cEC-EXs and 7.9% of total cEXs were CD34+KDR+ cEPC-EXs.
0.97 CD144+ cEC-EXs and CD34+KDR+ cEPC-EXs in patients at days 1, 3, and 5 after admission.
0.96 CD144) and EPCs (CD34, KDR) were evaluated.
0.96 CD144 and anti-CD34/anti-KDR had the highest sensitivity and specificity for isolating and detecting EC-EXs and EPC-EXs, respectively.
0.94 CD34+KDR+ EXs was around 68% and of CD34+CD144+ EXs was only around 20% (Figure 3(b)).
0.93 CD34-Conjugated Microbeads Combined with Anti-CD144- or Anti-KDR-Conjugated Q-Dots Methods
0.88 CD34, CD41, and CD235a). (b) The detection efficiency and specificity of EC-EXs in the total CD105+ EXs that were labeled with CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots upon detection by fluorescence NTA. (c) The overall efficiency for measuring the CD105+ EXs colabeled with CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots in the total EC-EXs.
0.86 CD34+KDR+ EXs was around 69% and of CD34+CD144+ EXs was only 17% (Figure 5(b)).
0.75 CD34-Conjugated Microbeads Combined with Anti-CD144- or Anti-KDR-Conjugated Q-Dots from Particle-Free Plasma
0.64 CD144+ cEC-EXs and 8.3 x 106 CD34+KDR+ cEPC-EXs per mL plasma collected from day 1 after patient admission (Figures 6(a3) and 6(b3)).
0.56 CD34, KDR) has been used as surrogate markers for EPCs and CD105 and CD144 have been identified for ECs, we used these antibodies to establish the method.
31257478 0.98 CD34, cadherin 5 (CDH5), Fms related tyrosine kinase 1 (FLT1) and asporin were hub nodes in the PPI network of DEGs.
0.98 CD34 (degree=10, downregulated), CDH5 (degree=10, downregulated), FLT1 (degree=10, downregulated) and ASPN (degree=7, downregulated) were considered to be hub nodes in the network, as they had the highest connectivity degree.
0.98 CD34, and CDH5 in OA are shown in Table SI.
0.98 CD34 and CDH5 together with ASPN, were hub nodes in the PPI network of DEGs.
0.97 CD34 and CDH5 in acetabular labrum cells may be involved in the pathogenesis of OA and could serve as biomarkers and therapeutic targets of OA.
0.97 CD34 and CDH5 were present in the yellow subnetwork, and FLT1 and ASPN were present in the turquoise subnetwork.
0.97 CD34 and CDH5 were associated with the most abundant biological functions and may be substantially involved in the development and progression of OA.
0.97 CD34 and CDH5 may be involved in the development and progression of OA.
0.95 CD34, and CDH5.
0.88 CD34 and CDH5 were the key genes associated with the most abundant biological functions.
0.70 CD34, CDH5 and ASPN in the OA labrum.
27789903 0.98 VE-cadherin and VEGF protein expression levels were significantly elevated (p<0.05), while the dynamic perfusion culture significantly reduced the expression of CD34 (p<0.05) (Figure 5).
0.97 VE-cadherin and VEGF, but downregulated the expression level of CD34, at both the mRNA and protein levels.
0.96 CD34, VE-cadherin, and VEGF.
0.96 CD34 and acquired other endothelial markers, such as VE-cadherin.
0.95 CD34, VE-cadherin, and VEGF protein were 1.216+-0.105, 0.693+-0.011, and 0.784+-0.051 in the static culture group (n=4), Relative expression level of CD34, VE-cadherin, and VEGF protein were 0.992+-0.133, 1.074+-0.080, and 1.202+-0.126 in the dynamic perfusion culture group (n=4).
0.92 CD34/VE-cadherin/VEGF mRNA expression (* p<0.05, ** p<0.01).
0.81 CD34/VE-cadherin/VEGF mRNA in cells under the dynamic perfusion culture (n=4) were compared to static culture group (n=4).
0.71 CD34, VE-cadherin, and VEGF protein under static culture and dynamic perfusion culture. (* p<0.05)
25418725 0.98 CD34+CD31+ endothelial progenitors also expressed CD144 (VE-cadherin), but not CD45, indicating these cells were not in hematopoietic lineages (Figure S1).
0.98 CD144, vWF, ICAM-1, and KDR, but did not express CD117, CD34, or TIE-2 (Figure 6).
0.97 CD34+ cells in endothelial medium on laminin-coated plates and found that the resulting CD34+CD31+vWF+CD144+ endothelial cells were capable of approximately 20 population doublings over 2 months, generating more than 1 million cells from a single endothelial cell (Figure 7A).
0.92 CD34, CD144, but did not express vWF or intercellular adhesion molecule 1 (ICAM-1) (Figure 6).
0.86 CD34 diminished, whereas the cells retained expression of CD31+ and VE-cadherin (Figure 4C).
31245040 0.98 CD34+CD31+ gate using CD42a and CD144 and initiated into culture: CD45-CD34+CD31+CD144+CD42a-; CD45-CD34+CD31+CD144+CD42a+; CD45-CD34+CD31+CD144-CD42a+ and CD45-CD34+CD31+CD144-CD42a- (Figure 3A).
0.94 CD144 (top), CD146 (middle) and CD133 (bottom) expression on either isotype (black line), CD31+CD34- (gray-shaded), CD31+CD34lo (blue-shaded) or CD31+CD34hi (red-shaded) from EndoGo day 14 expansion.
0.93 CD34+ and CD34- EC subpopulations were CD144+, CD146+ and CD42a-.
0.92 CD34+CD31+CD144+CD42a- population, exhibited higher differential expression of CD34+ and CD31+.
0.84 CD144 and CD146 in all populations were observed suggesting EndoGo targeting CD133 and CD34 expression on the EPC.
27043316 0.98 CD34+ and CD34- fractions had comparable expressions of VE-cadherin, CD31, and VEGFR2 measured by FC, which were the same as in ECFCs before separation, which confirms the endothelial nature of both fractions (not shown).
0.97 VE-cadherin mRNA levels in PB-ECFCs transfected with siRNA CD34.
29569827 0.98 CD34, CD45, Ve-Cadherin (CD144), and cKIT (CD117) 43.
26395760 0.97 CD34, KDR (VEGFR2 or FLK1), CD31 (PECAM1), and CD144.
0.97 CD34+CD31+CD144+ cells give rise to hematopoietic cells from HEPs through hemogenic EC intermediate, we isolated CD34+CD31+CD144+ cells from EBs between day 6 and 8, and cultured them to form endothelial cell monolayer in a serum-free endothelial cell growth medium (ECGM) containing VEGF-A and FGF2.
0.97 CD34+CD31+CD144+ cells remained positive for CD34, CD31, and CD144, but negative for CD235a (Glycophorin A), CD41, CD117, and CD45 (Fig. 2C), indicating that EC monolayer contained no pre-committed hematopoietic cells.
0.97 CD34+CD31+CD144+ cells.
0.97 CD34+CD31+CD144+ cells, we switched the culture medium from ECGM to hematopoietic cell growth medium (HCGM) containing SCF, TPO, and F3L for 3 days, and then scored hematopoietic clusters.
0.97 CD34+CD31+CD144+ cells in endothelial cell growth condition for varying periods of time (0, 24, 48, and 72 h) before switching to hematopoietic growth conditions.
0.97 CD34+CD31+CD144+ cells co-expressed KDR (VEGFR2/FLK1), a mesodermal marker expressed in early precursors of hematopoiesis in the hPSC differentiation system, whereas they were negative for CD45 and CD117 (c-Kit), markers expressed in human HSPCs from AGM.
0.97 CD34+CD31+CD144+ cells as a transient population that declined quickly and diminished in 4 days of endothelial culture.
0.97 CD34+CD31+CD144+ cells were isolated by FACS.
0.97 CD34+CD31+CD144+ cells derived from H1 cells in ECGM for 24 h, erythroid differentiation was induced in HCGM containing SCF (S), F3L (F), TPO (T), and with or without EPO (E).
0.96 CD34+CD31+CD144+ cells were capable of generating multilineage hematopoietic cells in endothelial cell growth condition; and this capability is enhanced significantly in hematopoietic cell growth medium (HCGM) containing SCF, TPO, and F3L (Fig. 7A).
0.96 CD34+CD31+CD144+ cells were isolated from EBs between day 6 and day 8, and cultured on collagen-I coated plates in serum-free endothelial cell growth medium (ECGM) for 24 h. Unattached hematopoietic committed cells were removed, and attached endothelial cells were cultured either in ECGM or in hematopoietic cell growth medium (HCGM) for an additional 3 days.
0.96 CD34+CD31+CD144+ cells during hPSC differentiation.
0.95 CD34+CD31+CD144+ cells had hemogenic potential.
0.95 CD34+CD31+CD144+ cells were cultured in ECGM.
0.92 CD34+CD31+CD144+ cells.
0.92 CD34+CD31+CD144+ cells (Top Panel).
0.91 CD34+CD31+CD144+ population from hPSCs contains hemato-endothelial progenitors (HEPs) that give rise to hematopoietic cells and endothelial cells.
0.91 CD34+CD31+CD144+ cells in endothelial growth condition resulted in complete loss of ability to generate hematopoietic clusters (Fig. 7C).
0.91 CD34+CD31+CD144+CD41-CD43-CD73- cells.
0.91 CD34+ cells, CD31+ cells, and CD144+ cells (left panel) and kinetics of CD34+CD31+CD144+ cells (right panel) during hPSC differentiation by flow cytometric analysis.
0.89 CD34+CD31+ cells were gated for CD144+ and KDR+ (VEGFR2/FLK1) cells.
0.88 CD34+CD31+CD144+ cells.
0.87 CD34+CD31+CD144+ population is endowed with hemogenic activity to generate definitive MPP cells that gave rise to multilineage hematopoietic cells, including definitive erythroid cells and T lymphocytes.
0.87 CD34+CD31+ cells were CD144+CD73- cells on EB day 6, and CD144+CD73- cells significantly decreased after EB day 6.
0.77 CD34+CD31+CD144+ cells also appeared as early as day 4 and peaked around day 8 (Fig. 1B right panel).
0.77 CD34+CD31+CD144+ cells for 24 h to form an endothelial monolayer and removing unattached cells, the attached cells were photographed by a time-lapse microscope (Leica AF6000 LX System).
0.59 CD34+CD31+CD144+ cells expressed CD41, CD43, and CD235a (Fig., 4 1), suggesting that the CD34+CD31+CD144+ population contains primitive hematopoietic cells.
0.58 CD34+CD31+CD144+ population derived from hPSCs contain hemato-endothelial progenitors (HEPs) that give rise to hematopoietic and endothelial cells.
0.56 CD34+CD31+CD144+ cells expressed CD43 and CD235a, the markers of primitive hematopoietic cells at early hematopoietic developmental stage.
19038685 0.97 CD34-CD144-, FAC 19.6 +- 2.9%, Figure 1E).
0.97 CD34+CD144+ endothelial cells (Figure 3C).
0.97 CD34+CD144+ myoendothelial cells regenerated more fskMyHC expressing myocytes than did CD56+CD34-CD144- myogenic and CD56-CD34+CD144+ endothelial cells (* P<0.05).
0.96 CD34-CD144-CD45- cells, 45.8x104 CD56-CD34+CD144+CD45- cells, and 8.8x104 CD56+CD34+CD144+CD45- cells.
0.96 CD34+CD144+ cell-injected heart 2 weeks after cell transplantation.
0.94 CD34+CD144+) after FACS isolation.
0.92 CD34+CD144+) and myoendothelial cells (CD56+CD34+CD144+) changed after expansion in tissue culture flasks.
0.91 CD34+CD144+ cells (myoendothelial), we did not observe measurable expression in CD56+CD34-CD144- (myogenic) and CD56-CD34+CD144+ (endothelial) cells (data not shown).
0.91 CD34+CD144+) cells is a good indicator of their enhanced ability to improve cardiac function.
0.91 CD34+CD144+ cells either significantly decreased or was not detectable after 24 hours of hypoxia.
0.87 CD34-CD144- cells, CD56-CD34+CD144+ cells, and CD56+CD34+CD144+ cells.
0.85 CD34+CD144+ cells was observed when cultured under hypoxia for 24 hours in comparison to control normoxic conditions.
0.84 CD34+CD144+ cells when compared to the other groups.
0.81 CD34 and CD144) surface markers.
0.79 CD34+CD144+ cells compared with other groups at both 5 days and 6 weeks after cell transplantation (*P<0.05, CD56+CD34+CD144+ cells versus CD56+CD34-CD144- cells, CD56- CD34+CD144+ cells, and PBS).
0.76 CD34+CD144+CD45-) represented 1.8% of the total cell population, while endothelial cells (CD56-CD34+CD144+CD45-) and myogenic cells (CD56+CD34-CD144-CD45-) accounted for 9.0% and 2.6%, respectively.
0.74 CD34+CD144+ myoendothelial cell group also displayed greater LV contractility, as measured by fractional area change (FAC), when compared to the other groups at both the 2 and 6 weeks time points ( P<0.05, CD56+CD34+CD144+ cells versus CD56+CD34-CD144- cells and PBS).
0.72 CD34+CD144+) cells but not in the other tested cell populations.
0.71 CD34+CD144+ cells versus PBS).
0.68 CD34+CD144+ cells display a higher capillary density within the infarct when compared to the other groups (*P<0.05, CD56+CD34+CD144+ versus CD56+CD34-CD144- and CD56-CD34+CD144+; P<0.05, all cell groups versus PBS).
26417289 0.97 CD34, vWF, Pecam1 and Cdh5 (Figure 1(Fig. 1))).
0.95 CD34 and cadherin-5 in treated groups.
0.94 CD34 and Cdh5 gene expression or CD34 protein synthesis.
0.92 CD34 and Cdh5 appeared after 12 hours FSS application.
0.87 CD34 and cdh5 in MSCs and further culture of these CD34 cells induced them to express vWF and Pecam1.
0.82 CD34 and Cdh5 mRNA expression in 5% PL treated cells compared to other groups in the same time (groups 1-15, P<0.001).
0.82 CD34 and Cadherin-5 mRNAs in estradiol treated and non-treated groups.
0.80 CD34 and Cadherin5 (Cdh5) among cells.
0.75 CD34 and Cdh5 are endothelial progenitor specific markers while vWF and Pecam1 are known as specific markers for mature endothelial cells.
0.63 CD34 and Cdh5 in treated groups and the results were not significantly different when compared to group 16.
31839543 0.97 CD144+/CD73+/CD34+/CD45-) under endothelial conditions.
0.97 CD144 expression), EHT, and finally generation of CD45+/CD34+ SLGE-HPCs, suggests that the SLGE-based forward programming recapitulates early stages of embryonic hematopoiesis and mimics important developmental stages in vitro.
0.96 CD34+/CD38-/CD45RA-/CD90high/CD49fhigh-expressing cells (Figure S5) and compared with SLGE-iPSCs (TRA-1-60+/SSEA4+) and SLGE-HEPs (CD144+/CD73-).
0.91 CD144+/CD73-/CD43+/-/CD235a+/-/CD117+/CD34-/+/CD45- (gated on FMO).
0.91 CD144+/CD73+/CD34+) within 7 days of cultivation in EGM2 (endothelial growth medium) without Dox-induced TF expression (Figure S3A).
0.85 CD144+ cells showed a notable increase in CD34 expression with subsequent CD144 downregulation, resulting in an almost complete loss of endothelial signature by day 11.
0.80 CD144 as well as hematopoietic markers CD45 and CD34.
0.74 CD144+/CD73-), which produce hematopoietic progenitor cells (CD45+/CD34+/CD38-/CD45RA-/CD90+/CD49f+) through a gradual process of endothelial-to-hematopoietic transition (EHT).
0.59 CD144+/CD73-) capable of producing hematopoietic progenitor cells (CD45+/CD34+) with multi-lineage potential.
20037738 0.97 CD34, CD144).
0.95 CD34 and CD144 are expressed only in the endothelial lumen of the UC vessels.
0.91 CD34, endothelial cell markers CD144 and CD146, and MSC markers CD44, CD105, CD73, and CD90 (Figure 1(d)) and the percentage of cells expressing these markers was quantified (Figure 1(e)).
0.91 CD34, CD144, or CD146); rather there is remarkable stability and maintenance of the population phenotype.
0.84 CD34, CD144, CD146, CD44, CD105, CD73, and CD90.
0.63 CD34 (P < .001), CD144 (P < .001), and CD146 (P = .049), and CD73 (P < .001) which was also detected in the endothelium.
0.54 CD34 (absent) and CD144 (5.0% at week 1 and 0.7% at week 3 Figures 2(e) and 2(f)).
24341512 0.97 VE-cadherin, vWF, VEGF-R1 and VEGF-R2 mRNA in CD34+ cultured with or without PT45-CM.
0.97 CD34+ VEGF-R2+ cell differentiation along the endothelial lineage, this differentiation being characterized by the expression of vWF and VE-cadherin.
0.97 CD34+ cells began to express specific endothelial markers, namely CD146, CD105, VE-cadherin and vWF, and a subset of cells started to express VEGF-R1 RNAm.
0.92 CD34+ cells cultured for 19 days with or without PT45-CM, under conditions that support myeloid differentiation, were analyzed for endothelial-cell-marker expression, by flow cytometry (CD146 and CD105) and by immunohistochemistry (vWF and VE-cadherin).
0.90 VE-cadherin, vWF and in particular the VEGF-R1 (flt-1) transcripts were more strongly expressed in CD34+ cells cultivated in the presence of PT45-CM, versus controls (p = 0.03, p = 0.03 and p = 0.02, respectively).
0.53 VE-cadherin and vWF in CD34+ cells cultured with or without PT45-CM.
0.51 VE-cadherin and vWF, both of which are endothelial-specific markers, in a subset of cultured CD34+ cells (24 +- 8% and 23 +- 10%, respectively).
28854900 0.97 CD34, and VE-cadherin in both HT29 and SW480 cells.
0.95 CD34, and VE-cadherin and promoted HCT116 cells to form tube-like structures.
0.95 CD34, and VE-cadherin.
0.95 CD34, and VE-cadherin in HCT116 cells under hypoxia or normoxia were determined by western blotting (left) and immunofluorescent staining analysis (right).
0.93 CD34, and VE-cadherin) and had increased ability to form tube-like structures in 3D culture in vitro.
0.92 CD34, and VE-cadherin in HT29, SW480 or HCT116 after cultured for 5, 10 or 15 days in endothelial-inducing conditioned medium were determined by western blotting analysis.
0.86 CD34, and VE-cadherin (Fig. 2b).
32154424 0.97 CDH5 (orange), and CD34 (red) in differentiated cells just before purification on day 8, non-purified cells on day 10, and purified cells on day 10 derived from hiPS 610B1 cells.
0.96 CDH5, CD34, KDR, vWF, and MMP1 of iEPCs derived from two different iPS cell lines and HUVECs.
0.95 CDH5, CD34, KDR, and vWF in purified iEPCs on day 8 derived from three hiPS cell lines and HUVECs.
0.94 CDH5 (orange), and CD34 (red) in purified iEPCs differentiated under the XF condition (XF-iEPCs) on day 10.
0.93 CDH5, and CD34 (Figure 2C).
0.89 CDH5, and CD34.
0.63 CDH5 were localized on the cell membrane, whereas CD34 was in the cytosol of iEPCs (Figure 2B).
24749070 0.97 CD34, VE-cadherin, and CD45 expression in cells from the AoV, AoD, and UGRs.
0.96 CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+CD38-/loCD45RA-.
0.95 CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+CD38-/loCD45RA- phenotype defines the identity of the earliest human HSCs and provides up to 1,000-fold enrichment for HSCs in the total AGM region cell population.
0.95 CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+CD38-/loCD45RA-.
0.94 CD34+CD45+ cells from the human AGM region largely coexpress VE-cadherin, an important marker for early HSCs in the mouse embryo.
0.90 CD34, C-KIT, THY-1, endoglin, RUNX1, CD38, and CD45RA expression in the VE-cadherin+CD45+ cell population.
19364973 0.97 CD34 images shown at 4x magnification (scale bar=100 microns), CD31/AcLDL and VE-Cadherin/eNOS shown at 20x magnification (scale bar=20 microns).
0.95 CD34 (Figure 1C) and VE-Cadherin (not shown).
0.92 CD34, VE-Cadherin, endothelial nitric oxide synthase (eNOS), and absorbed acetylated LDL (Figure 2).
0.81 CD34 or VE-Cadherin (not shown).
0.66 CD34 and VE-Cadherin occurred prior to or during the peak of NRP-1 cell surface protein expression.
20219017 0.97 CD144, CD34, CD31, UEA-1 receptor.
0.97 CD144, CD34, CD133 and the UEA-I receptor (Table 3).
0.97 CD34 and CD144, thus excluding any myogenic and endothelial cell contamination (Fig. 4).
0.96 CD34, CD144) and hematopoietic markers (CD45, CD34).
0.91 CD34 and CD144 by RT-PCR (Fig. 4), CD34, CD133 and CD144 by flow cytometry (Fig. 3) and CD34, CD144, CD133, vWF and Ulex europaeus receptor by immunofluorescence (Table 3).
22821929 0.97 CD34 and CD144, suggesting that transplantation of a subpopulation of these cells may lead to greater functional recovery.
0.97 CD34 or CD144 released more pro-angiogenic and anti-apoptotic factors than other subpopulations of piPSC-ECs and pASCs.
0.97 CD34+/CD144-, 2) CD31+/CD34-/CD144+, and 3) CD31+/CD34-/CD144-
0.91 CD34 and CD144 (or VE-cadherin).
0.91 CD34 and CD144 augment angiogenesis by release of paracrine factors.
23226561 0.97 CD144 and CD45 expression analysis of adherent cells generated by CD34+ cells cultured in MH-CM for 30 days, then transferred to haematopoietic medium (i.e. day 33 = day 3 in haematopoietic medium, day 36 = day 6 in haematopoietic medium and so on).
0.97 CD144+CD45+ haematopoietic progeny display a number of features commonly observed in hemopoietic cells derived from CD34+ cells isolated from cord blood.
0.96 CD34+ progenitors; in long- term MH-CM culture we obtained growth of: (i) a bulk CD34+ population differentiating toward the endothelial lineage and (ii) single CD34+ cells expressing both haematopoietic (CD45) and endothelial (CD144) markers.
0.79 CD34+ cells, which gradually gave rise to two different populations: i) one floating and round shaped, composed of CD45+ haematopoietic cells and ii) one firmly attached to the wells, which acquired endothelial morphology and became CD144+.
0.71 CD144, CD146, CD147, CD105 (endothelial markers), CD34 (haemato-endothelial marker), CD29, CD44 (mesenchymal markers) CD61, i.e. beta3 integrin-GPIIIa (megakaryocytic-endothelial-osteoclastic marker) and CD13, i.e. aminopeptidase N (myeloid-endothelial marker).
26635885 0.97 CD34+ cells and the population of EPCs delineated by such phenotypes as CD34+CD144+, CD34+CD133+, and CD34+CD133+CD309+ cells.
0.97 CD34+CD144+ cells (Figure 4(b)), CD34+CD133+ cells (Figure 4(c)), and CD34+CD133+CD309+ cells (Figure 4(d)).
0.97 CD34+CD144+CD309+ cell numbers, the PBMC events were displayed on the basis of FMO control sample (e) and gates were set to exclude the random noise.
0.95 CD34+CD144+, CD34+CD133+, and CD34+CD309+CD133+ cells) in fifteen female patients subjected to the FSH therapy.
0.93 CD34+CD144+ cells (upper right quadrant, Q2) were gated based on CD34/CD144 dot plot (d).
27693424 0.97 CD34, KDR, PECAM1, and CDH5) was analyzed on days 0, 3, 5, 7, 9, and 11 without purification, normalized to GAPDH.
0.97 CD34+ and VEGFR2+CD31+VE-Cadherin+) on either LN521 or LN521/421 substrate.
0.92 CD34+CD31+VE-Cadherin+.
0.92 CD34+VEGFR2+CD31+VE-Cadherin+ population after 15 days.
0.88 CD34+, 96% CD31+, and 95% VE-Cadherin+ populations, whereby 94% of the final culture was triple-positive for VEGFR2, CD31, and VE-Cadherin (Figures 3A and 3B).
22652782 0.97 CD34- monocytes, isolated from PBMCs, express EC markers such as von willebrand factor (vWF), VE-cadherin and eNOS.
0.95 CD34+VEGFR-2+Tie-2+CD31-CD144-, whereas the outgoing VW-EPCs become CD144+.
0.95 CD34/CD144, implying that MOMCs correspond to early EPCs.
28381471 0.97 CD34+ progenitors to iECs as demonstrated by suppression of the EC-specific markers (VE-cadherin, CD31, and FLK1) at both mRNA and protein levels when compared with scrambled shRNA (Figure 5D through 5F).
0.96 CD34+ cells were also evaluated for their clonal expansion potential and the pluripotency surface markers TRA-160 and TRA-180, endothelial surface markers VE-cadherin and CD31, and the erythroblast/erythrocyte surface marker CD235a by flow cytometry.
0.72 VE-cadherin+ iECs continued to express CD34 after endothelial differentiation (Figure IIE in the online-only Data Supplement).
30053898 0.97 CD34+CD144+ hemogenic endothelial cells.
0.89 VE-cadherin, CD34 and CD43 (Fig. 2d, i-iii), indicating a dual-differentiation potential stage.
0.52 CD34 and VE-cadherin (both green), and CD43, CD31 and CD45 (all red).
18755033 0.97 CD34 and CD144 were found abundantly expressed (i.e., >100 copies/mug RNA) in the total study cohort whereas only very few KDR or CD133 gene transcripts were detectable (figure 5B).
0.93 CD34, KDR or CD133 by 4-color flow cytometry and for the expression of CD34, CD133, KDR and CD144 by qPCR.
20539287 0.97 CD34, KDR-Flk-1, VE-cad and vWF (Fig. 2), and incorporate ac-LDL.
0.64 CD34+ -based isolations yielded EC populations with similar characteristics, as demonstrated by their typical endothelial cell morphology as well as expression of typical endothelial markers such as CD31, CD34, KDR-Flk-1, VE-cad and vWF (Figs. 1 and 2).
22605545 0.97 VE-cadherin, PECAM-1, CD34, VEGF-R1 and VEGF-R2 after 10days of stimulation.
0.97 CD34-, vascular endothelial cadherin- (VE-cadherin-), AC133+, and fetal liver kinase+ (Flk1+), when cultured with VEGF differentiated into CD34+, VE-cadherin+, Flk1+ cells, a phenotype that would be expected for angioblasts.
24837661 0.97 CD144, CD117 and CD45 on CD34+CD43- populations, as in (1F).
0.95 CD34 or CD144.
30449319 0.97 CD34, VE-cadherin (CD144), and KDR, and lacking the expression of CD43, CD41, and CD45 marking hematopoietic commitment as well as lacking the expression of DLL4, CD73, and CD184, marking further endothelial commitment or arterial specification.
0.90 CD144+ co-expressing KDR and CD34 but lacking the expression of the hematopoietic markers CD41, CD43, and the expression of the endothelial markers CD73, DLL4, and CXCR4.
18493616 0.97 Ve-cadherin and CD31 endothelial markers from both normal and dystrophic CD133+CXCR4+CD34- cell populations.
21858032 0.97 VE-cadherin (CD144) and VEGFR-2 (CD309), revealed that early EPCs expressed CD144 and CD309, in addition to the beta3-integrin subunit (CD61) and the beta2-integrin subunit (CD18), whereas the expression of CD45 and CD34 was low (Fig. 2B).
27966446 0.97 VE-cadherin expression with poor survival in a subset of melanoma patients and breast cancer patients showing low CD34 expression.
29374149 0.97 CD144, CD31, vWF, FLK-1, FLT1, KDR and CD34) became robustly up-regulated as time progressed (Fig. 3a).
29467489 0.97 VE-Cadherin, CD34 expression has also been used to identify populations of cells with a hemato-endothelial phenotype.
30400266 0.97 CD34, CD133, CD31, CD144, KDR, CD146, von Willebrand factor (vWF)) and hematopoietic immune cells (CD3, CD14, HLA DR, CD45).
27094208 0.96 CD144+ EC-MV and CD34+KDR+ EPC-MV isolation and detection were approximately 70%, which are consistent with the data we obtained for developing the methods in the culture systems.
0.95 CD144+ EC-MVs and CD34+KDR+ EPC-MVs were over 70%, respectively.
0.91 CD144+ EC-MVs and CD34+KDR+ EPC-MVs were above 70%.
0.91 CD34+ MVs that were labeled with secondary antibodies (CD144, or KDR, or Annexin V, or CD63) conjugated with Q-dots and analyzed by fluorescent NTA.
0.90 CD34: specific for endothelial progenitor cells; CD105: specific for endothelial cells; CD144: vascular endothelial antigen; KDR: EPC antigen; Annexin V: MV specific antigen; CD63: exosomal specific antigen.
0.89 CD144 of ECs, and EPC-microparticles express CD34 and KDR of EPCs.
0.88 CD34 (EPC marker) conjugated-microbeads had the highest sensitivity and specificity for isolating respective MVs, which were confirmed with negative controls, CD41 and CD235a; 2) anti-CD144 (EC marker) and anti-KDR (EPC marker) conjugated-Q-dots exhibited the best sensitivity and specificity for their respective MV NTA detection, which were confirmed with positive control, anti-Annexin V (MV universal marker).
0.88 CD34) conjugated microbeads for isolation and cell specific antibody (anti-CD144 or anti-KDR) conjugated Q-dots for NTA detection can offer highly sensitive and specific methods for detecting cEC-MVs and cEPC-MVs.
0.87 CD144+ cEC-MVs and 8 x 106 CD34+KDR+ cEPC-MVs in per ml plasma collected from day 1 after patient admission (Fig. 4a3,b3).
0.83 CD34) expression cannot define EC-MVs or EPC-MVs specifically, we applied the surface antigens (CD144 and KDR) conjugated to Q-dots to simultaneously label the microbeads captured MVs.
0.83 CD34 as well as negative controls, CD41, CD235a). (a2,b2) the detection efficiencies and specificities of EC-MVs in the total CD105+ MVs, or EPC-MVs in the total CD34+ MVs, that were labeled with CD144-, or KDR-, or Annexin V-, or CD63- conjugated Q-dots upon detected by fluorescence NTA. (a3,b3) the overall efficiency for measuring the CD105+ MVs or CD34+ MVs co-labeled with CD144-, or KDR-, or Annexin V-, or CD63- conjugated Q-dots in the total EC-MVs.
0.77 CD144+ MVs or CD34+KDR+ MVs (Fig. 3a4,b4) were significantly higher as detected by fluorescence NTA than that detected by flow cytometry, suggesting the high sensitivity of NTA for detecting MVs and reflecting that the MV size is not affected by the biological complex of plasma.
0.70 CD144+ EC-MVs or CD34+KDR+ EPC-MVs was almost two-orders of magnitude higher enumerated by NTA than that counted by the flow cytometer, which suggest that the established methods were much sensitive than flow cytometer in detecting these nanoscale particles.
0.60 CD144+ EC-MVs, and 8% of cMVs were CD34+KDR+ EPC-MVs in the day 1 plasma samples.
22981233 0.96 VE-cadherin and CD31, they expressed other markers typically found on endothelial cells including TEK, CD34, CD201, and CD146 (Figures 4B and S5A) suggesting that these mesodermal cells could be direct precursors of endothelial progenitors in hESC cultures.
23202434 0.96 CD34+ cells towards the endothelial lineage, gave rise to 60-90% VE-cadherin+ endoglin+ cells in all cell lines analyzed.
29304136 0.95 CD34+/VE-cadherin+ cells.
0.93 CD34+/KDR+, CD34+/VE-cadherin+) and smooth muscle (CD14+/endoglin+) progenitor cells were identified by flow cytometry.
0.89 CD34+/KDR+ and CD34+/VE-cadherin+ diminished and CD14+/endoglin+ increased is associated with higher cardiovascular risk.
0.78 CD34, CD133) and endothelial [KDR (a vascular endothelial growth factor receptor), VE-cadherin, von Willebrand factor or CD31] surface markers that have demonstrated their capacity to maintain the integrity of the blood vessels by homing into sites of endothelial injury and differentiating into mature endothelium.
19658191 0.95 CD34 and VE-cadherin.
0.93 VE-cadherin-/CD34- Type I EOC cells can differentiate into a CD44+/VE-cadherin+/CD34+ phenotype after vessel formation in Matrigel.
0.85 VE-cadherin expression, Type I EOC cells also gained CD34 expression after Matrigel differentiation (Fig. 3b).
24391835 0.95 CD34+ cells were CD34+/CD133+ (69.5+-11.3%), and 3.8+-2.1% of the cells were CD34+/CD133+/CD144+.
0.92 CD34 was expressed in 91.2+-4.8% of immunomagnetically isolated UCB CD34+ cells, and the other analyzed antigens were expressed as follows: CD133, 72.1+-12.6%; CXCR4, 74.9+-13.1%; and CD144, 5.5+-1.8%.
0.79 CD34+/CD133+/CD144+ EPCs (1.7%).
27676263 0.95 CD34, CD133, VEGFR-2 (KDR/FLK-1/CD309), VE-Cadherin (CD144), Tie-2, etc., or combination of multiple molecules.
0.89 CD144 (VE-Cadherin), CD146, CD31) and an endothelial progenitor marker (CD34).
0.77 VE-Cadherin, CD31 (PECAM-1), and CD34, have also served as OEC markers.
18301744 0.95 VE-cadherin, VEGFR2, CD34, CD31 and CD105, and all of the cells were negative for a panleukocyte marker CD45, monocyte/macrophage marker (CD11b), and stem/progenitor makers (AC133 and c-kit) (Figure 1a).
0.95 VE-cadherin (1.6%), VEGFR2 (5.4%), and von Willebrand Factor (vWF) (0.3%), or the stem/progenitor cell markers AC133 (1.0%), c-kit (0.4%), and CD34 (0.2%).
28803914 0.94 CD34 and KDR, CD144, and CD31 on WT, KO + GFP, and KO + HEBCan d8 EB-derived cells.
0.91 CD34, CD309 (KDR), CD31 (PECAM-1), and CD144 (VE-cadherin), all of which mark mesoderm-derived endothelial cells (Figure 3D).
0.91 CD34+ cells that were also positive for KDR, CD144, and CD31, consistent with the presence of HE.
0.70 CD34 and KDR, CD144, and CD31 expression on d8 EB-derived cells.
26283734 0.94 CD144 (B) surface expression of Lin-CD34highCD45mid population when first isolated and then when placed in vitro under conditions to maintain the undifferentiated state or the differentiated state (n = 4).
0.90 CD34+ cells to promote differentiation failed to show a characteristic gain in differentiation marker CD144 under endothelial-supporting conditions (Fig. 4B), suggesting defects in the ability both to maintain "stemness" and to differentiate toward endothelial cells.
0.86 CD144 expression in CD34+ cells under hematopoietic and endothelial culture conditions.
30847424 0.94 CD34 and primitive (CD133), early myeloid (CD33), migratory (CXCR4), endothelial adhesion (CD144), or pericyte (CD146) cell surface markers.
0.93 CD34 and platelet endothelial cell adhesion molecule-1 (CD31) was equivalent between patients with T2D and control subjects (Figures 3A to 3C), primitive (CD34+) cells expressing vascular endothelial-cadherin and the pericyte marker CD146 were decreased in patients with T2D compared with control subjects (Figures 3D to 3I).
26042795 0.93 CD34, CDH5 and CD31 was detected at day 4 and increased at day 5 (Fig. 2A).
27391301 0.93 CD34+CD43- cells promoted the formation and expansion of VE-cadherin+CD43+CD45- semiadherent cells that produced blood cells following SOX17 downregulation.
24348676 0.92 CD34+CD144+ phenotype (P = 0.04).
0.86 CD34+CD144+ phenotype.
0.57 CD34+CD144+ subset is significantly enriched in T1D patients.
25057108 0.92 CD34dim, CD146-, 7-AAD- circulating cell population utilising ultramicro analytical immunochemistry showing that these events have multiple detectable endothelial cell proteins (CD31 CD34, CD62E, CD105, vWF, CD141, CD144 and CD146).
0.85 CD34, CD105, CD141, CD144 and CD146 were similarly expressed on HUVECs and the CD45-, CD34dim, CD146-, 7-AAD- population.
23388453 0.92 VE-cadherin+ cells were homogenous in expression of CD31, ESAM and other typical endothelial markers such as TEK, KDR, CD34, CD141, CD146 and CD201, we were able to discriminate the following distinct subsets within this population based on expression of the endothelial/mesenchymal marker CD73 (5'-nucleotidase) and the hematopoietic markers, CD235a and CD43 (Glycophorin A and Leukosialin): (1) CD73-CD235a/CD43-; (2) CD73+ CD235a/CD43-; and (3) CD73-CD235a+CD43lowCD41a- cells.
27466317 0.92 VE-cadherin recruits the sialomucins CD34 and Podxl to the site of cell-cell contact, thereby initiating the separation of the two contacting cell membranes by way of repulsive forces mediated by the negatively charged carbohydrates on sialomucins.
23144795 0.91 CD34 and CD144 but a homogeneous expression of CD31, CD45, CD11b and CD14.
0.91 CD34 and CD144, low expression of CD117 and VEGFR2, and no expression of CD31.
0.90 CD34, CD144, CD45, CD11b and CD14.
26866427 0.91 CD34 without CD45, and expressed VEGFR-2 and VE-cadherin endothelial markers by late Stage-2, likely representing hemangioblasts or hemogenic endothelium as in human ESC studies.
0.65 CD34+CD45- putative hemogenic endothelial cells were observed in Stage-3 cultures, and expressed VEGFR-2/Flk-1/KDR and VE-cadherin endothelial markers, GATA-2, AML1/RUNX1, and SCL/TAL1 transcription factors, and endothelial/HSPC-associated microRNAs miR-24, miR-125a-3p, miR-126/126*, and miR-155.
28859673 0.91 VE-cadherin, CD34, PECAM-1.
0.88 VE-cadherin, vWF, eNOS, CD34, CD133 as shown in Table 2.
21603627 0.91 VE-cadherin+) cells as identified by flow cytometry over the starting (CD34+, CD45-, VE-cadherin-) population.
21029373 0.90 CD34 versus FL2-CD144 dot plots were utilized to recognize circulating CD144+ EPC/EC and to distinguish, within this class, the subpopulation of cells co-expressing CD144 and CD34 (H).
27512727 0.89 VE-cadherin+CD31+CD34+KDR+CD43- population.
0.89 VE-cadherin+, CD31+, and CD34+ populations on days 12 and 13 in H9 hESCs treated with DMSO, BIR1, and BIR2.
0.67 VE-cadherin, CD31, CD34, KDR, CXCR4, and UEA1 in H9 hESCs treated with DMSO, BIR1, and BIR2, and cultured till day 12.
29139170 0.89 CD34+, CD117+, CD144+, and CD73- to detect endothelial cells and CD41a+, CD43+, CD235a+ to monitor hematopoietic development.
0.86 CD34+CD31+ (27.5%+-6.6) and CD34+CD144+ (22.0%+-7.3) with limited numbers of hematopoietic progenitor cells, defined by CD34+CD41a+ (2.3%+-0.4), CD34+CD43+ (6.3%+-1.4), and CD34+CD45+ (1.2%+-0.6) (Figures 1C & 1D).
28717251 0.89 CD34-ECs revealed the typical junctional staining pattern of the endothelial markers CD31 and CD144.
22249946 0.87 CD34+ cells, whereas the vascular endothelial cell marker VE-cadherin was readily detectable in every cell (Fig. 2b).
0.56 VE-cadherin (red), but only a subset was stained for CD34 (green).
25562354 0.82 CD34+/CD31-/CD144- ASCs from endothelial cells (CD34+/CD31+/CD144+) by differential plastic adherence further supports distinct populations, with the majority of the ASC subset co-expressing MSC, pericytic and smooth muscle markers.
26153229 0.82 CD34+/VE-cadherin+ ECs are generated with equal potency across all conditions of activin A/BMP4 dosing.
24023546 0.81 CD34, CD144, and vWF.
27686241 0.75 CD34, CD45, CD117, CD31, CD43, CD38, CD144/VE-cadherin, CD133, CD90, and CD309/KDR presented on a subpopulation of different phase population, indicating the commitment of the hemangioblasts, hemogenic endothelium, hematopoietic stem cells, and hematopoietic progenitors in the cultures.
24497003 0.70 CD34+ cells residing in the interstitial spaces of muscle are related to endothelial cells, due to the expression profile CD56+CD34+CD144+ .
22128816 0.63 CD34+ and CD146+ cells and co-cultured them with basal and mobilized PBMNCs; both cell types took up Dil-LDL, but purified CD146+ cells exhibited accelerated differentiation by increasing expression of CD31 and CD144, and by exhibiting more active cord-like structure formation by comparison to the CD34+ subpopulation in a co-culture with mobilized PBMNCs.
25490403 0.61 CD34+ cells expressed VE-cadherin, Tie2 and CD31, all markers of endothelial cells.



The preparation time of this page was 0.0 [sec].